Investigational Drug Information for PF-04958242
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for PF-04958242?
PF-04958242 is an investigational drug.
There have been 14 clinical trials for PF-04958242.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 15th 2018.
The most common disease conditions in clinical trials are Schizophrenia, Cognitive Dysfunction, and Cognition Disorders. The leading clinical trial sponsors are Biogen, Pfizer, and Yale University.
There are forty-three US patents protecting this investigational drug and four hundred and thirteen international patents.
Summary for PF-04958242
| US Patents | 43 |
| International Patents | 413 |
| US Patent Applications | 113 |
| WIPO Patent Applications | 18 |
| Japanese Patent Applications | 16 |
| Clinical Trial Progress | Phase 1 (2018-11-15) |
| Vendors | 11 |
Recent Clinical Trials for PF-04958242
| Title | Sponsor | Phase |
|---|---|---|
| Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants | Biogen | Phase 1 |
| A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) | Biogen | Phase 2 |
| A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) | Biogen | Phase 2 |
Clinical Trial Summary for PF-04958242
Top disease conditions for PF-04958242
Top clinical trial sponsors for PF-04958242
US Patents for PF-04958242
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-04958242 | See Plans and Pricing | 2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,- 3-thiazol-4-yl amides | Pfizer Inc. (New York, NY) | See Plans and Pricing |
| PF-04958242 | See Plans and Pricing | Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors | Pfizer Inc. (New York, NY) | See Plans and Pricing |
| PF-04958242 | See Plans and Pricing | Imidazopyridazine compounds | Pfizer Inc. (New York, NY) | See Plans and Pricing |
| PF-04958242 | See Plans and Pricing | N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiaz- in-8a(8H)-YL)-1,3-thiazol-4-YL] amides | Pfizer Inc. (New York, NY) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-04958242
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-04958242 | Argentina | AR099997 | 2034-04-10 | See Plans and Pricing |
| PF-04958242 | Australia | AU2015245260 | 2034-04-10 | See Plans and Pricing |
| PF-04958242 | Canada | CA2944971 | 2034-04-10 | See Plans and Pricing |
| PF-04958242 | Chile | CL2016002510 | 2034-04-10 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
